Traders pushed Xeris Biopharma stock up 6 percent after word got out that H Lundbeck is sizing up a possible buyout. The Danish drugmaker has brought in advisers to look at a deal, according to Bloomberg sources. A Reuters report confirmed Lundbeck’s interest on September 29, 2026. No public offer has landed yet.
Xeris Biopharma develops therapies for endocrine and rare neuromuscular diseases, with three commercial products: Recorlev, Gvoke, and Keveyis.
The numbers show the scale. Xeris Biopharma’s market value sits at $1.79 billion. H Lundbeck is valued at 43.3 billion Danish kroner, or $6.6 billion, as shown in a Bloomberg Law analysis. A deal would be big. But Xeris is not open to talks about a buyout.
This is not new in biotech. Rumors alone can move stocks before any real talks start. Zymeworks’ $929 million buy of Theravance Biopharma is a recent example, as reported earlier.
Reuters highlighted that Xeris shares have risen more than 20% over the past year on the New York Stock Exchange, making the company a prominent target in the sector. However, there has been no signed agreement or official launch of a sale process.
Rumors can spark sharp moves in this market. Xeris Biopharma’s flat-out denial stands apart. The company is not talking sale, even with a strong market cap and interest from a much bigger European rival. For now, Xeris is sticking to its plan. Patients and pipeline come first. No deal.
